National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 21 of 41
An Observational Study of Childhood Food Allergy
NCT00356174
Rosiglitazone Effect on Mitochondria and Lipoatrophy
NCT00367744
Alternative Oseltamivir Dosing Strategies
NCT00334529
Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
NCT00320606
Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
NCT00076817
Cytomegalovirus Cell-Mediated Immunity
NCT00815165
Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
NCT00347672
Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants
NCT00308412
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults
NCT00270699
Urine Testing to Detect Kidney Transplant Rejection
NCT00337220
Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults
NCT00333398
Acute HIV Infection Observational Study
NCT00296660
gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
NCT00133497
CMV Infection in Adolescent Males
NCT00302029
Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
NCT00346398
Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People
NCT00078442
Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis
NCT00515047
Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes
NCT00324389
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
NCT00347555
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
NCT00325078
Cidofovir in Renal Transplant Recipients With BKVN
NCT00138424
Phase I Study of Vaccination Schedule of Experimental HIV Vaccines
NCT00321061
Directly Observed Therapy for HIV Infected Adolescents
NCT00259389
Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults
NCT00301184
St. Jude Open Label H5 Trial
NCT00311675
Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide
NCT00441909
Bacterial Pulmonary Infection in PICU
NCT00271531
Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications
NCT00433992
Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug
NCT00318747
PsA Treatment With hOKT3γ1 (Ala-Ala)
NCT00239720
Phase I Study of West Nile Virus Vaccine
NCT00300417
H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults
NCT00294099
Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
NCT00183261
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
NCT00307125
T and B Cell Response to Avian Flu Vaccine
NCT00337896
Use of Infliximab for the Treatment of Pemphigus Vulgaris
NCT00283712
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant
NCT00320658
Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients
NCT00308802
H5 Vaccine Alone or With Adjuvant in Healthy Adults
NCT00296634
Safety and Dose Study of Peramivir for Influenza Treatment
NCT00297050
Study of Factors Involved in Resistance to Severe Malaria
NCT00368810
Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy
NCT00286767
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
NCT00260078
TY800 Dose Escalation (Typhoid)
NCT00269295
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
NCT00257127
Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults
NCT00270218
CVD 909 Vi Prime Boost Study
NCT00326443
H5 Adult - Chiron Study of Bird Flu Vaccine
NCT00280033
Voriconazole Blood Levels and Toxicity
NCT00359541
Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research
NCT00277849
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.